InsiderTrades

Form 4 for IRWD IRONWOOD PHARMACEUTICALS INC

Accepted 2026-03-17 00:00:00 ET · period of report 2026-03-13 · accession 0001193125-26-111581 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
MI 2026-03-17 2026-03-17 IRWD DENNER ALEXANDER J Dir S - Sale $3.05 -6.73M 9.19M -42% -$20.53M
2026-03-17 2026-03-13 IRWD DENNER ALEXANDER J Dir A - Grant $0.00 +4,451 256.3K +2% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Class A Common Stock 2026-03-17 S D 5,800 $3.31 9,188,635 I — —
2 Common Class A Common Stock 2026-03-13 A A 4,451 $0.00 256,309 D See footnote — — (F2) Consists of shares that are held by Sarissa Capital Management LP ("Sarissa Capital") or by the funds and other investment vehicles (the "Sarissa Funds") for which Sarissa Capital serves as investment advisor. Dr. Denner is the Chief Investment Officer of Sarissa Capital and the managing member, general partner or other control party of the Sarissa Funds. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own the shares that these funds directly beneficially own. Each of SarissaCapital, the Sarissa Funds and Dr. Denner disclaims beneficial ownership of these shares except, in each case, to the extent of their pecuniary interest therein.
3 Common Class A Common Stock 2026-03-17 S D 6,725,000 $3.05 9,194,435 I See footnote — — (F2) Consists of shares that are held by Sarissa Capital Management LP ("Sarissa Capital") or by the funds and other investment vehicles (the "Sarissa Funds") for which Sarissa Capital serves as investment advisor. Dr. Denner is the Chief Investment Officer of Sarissa Capital and the managing member, general partner or other control party of the Sarissa Funds. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own the shares that these funds directly beneficially own. Each of SarissaCapital, the Sarissa Funds and Dr. Denner disclaims beneficial ownership of these shares except, in each case, to the extent of their pecuniary interest therein.